Trial · NCT06536166
Ruxolitinib Treatment in Inclusion Body Myositis
NCT06536166, Phase 2, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ruxolitinib Treatment in Inclusion Body Myositis. Trials, record NCT06536166. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06536166
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ruxolitinib Treatment in Inclusion Body Myositis
- NCT number
- NCT06536166
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Inclusion Body Myositis, Sporadic
- Interventions
- Ruxolitinib, Placebo
- First posted
- 2024-08-02
- Last updated
- 2026-05-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6 minutes-walk distance (6MWT): A distance walked in 6 min. superior in treated patients compared to placebo group | 12 months | The 6MWT is performed in a corridor, between two cones separated by a distance of 25 m. |
| Secondary | Adverse events (safety and tolerability) of ruxolitinib in IBM patients | Through study completion that is to say 15 months | Adverse events collected according to the MedDRA classification |
| Secondary | Therapeutic muscular efficacy of ruxolitinib on muscle strength | Until last consultation that is to say 12 months | Quantification of muscle strength using dynamometer |
| Secondary | Therapeutic muscular efficacy of ruxolitinib on overall muscle status | Until last consultation that is to say 12 months | Measurement of overall muscle status using scales and serum creatine kinase (CK) levels |
| Secondary | Respiratory ability | 12 months | Forced vital capacity (FVC) measurement |
| Secondary | Evaluate swallowing using Swallowing Disturbance Questionnaire (SDQ) | 12 months | Measurement of the swallowing disorders via Swallowing Disturbance Questionnaire (SDQ). 15 items. Overall score from 0,5 to 44,5. The score increase with the swallowing disorders. |
| Secondary | Lower limb quantification of fat replacement of muscle tissue, residual muscle tissue and markers of disease activity using MRI | 12 months | Measurement of the differences in fat fraction value calculated on thigh Dixon MRI pictures |
| Secondary | Evaluate quality of life using Health Assessment Questionnaire without Disability Index (HAQ-DI) | 12 months | Measurement of the difference in the quality of life measured by Health Assessment Questionnaire without Disability Index (HAQ-DI). 8 dimensions rated from 0 (without any difficulty) to 3 (unable to do). Overall score from 0 to 3. The higher the score, the lower the quality of life. |
| Secondary | Evaluate quality of life using Duke health profile | 12 months | Measurement of the difference in the quality of life measured by Duke health profile - The Duke. 10 dimensions. Overall score from 0 to 100. The score increase with the quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06536166
GET https://conductscience.org/api/trials/v1/NCT06536166/registered